Drugs Used in Therapy of Portal Hypertension

Overview

Journal Clin Liver Dis (Hoboken)

Specialty Gastroenterology

Date 2019 Jun 13

PMID 31186872

Citations 4

Authors

Dhiraj Tripathi

Affiliations

Soon will be listed here.

Citing Articles

The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis.

Reiberger T, Berzigotti A, Trebicka J, Ertle J, Gashaw I, Swallow R Trials. 2023; 24(1):293.

PMID: 37095557 PMC: 10123479. DOI: 10.1186/s13063-023-07291-3.

Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Without Cirrhosis and Decompensation.

Cheng H, Lin H, Lin H, Uang Y, Keller J, Wang L Front Pharmacol. 2022; 12:805318.

PMID: 35069216 PMC: 8777254. DOI: 10.3389/fphar.2021.805318.

Use of Non-Selective Beta-Blocker for Refractory Stomal Variceal Hemorrhage.

Mu X, Winsor W, Trahey J Case Rep Gastroenterol. 2021; 15(1):87-91.

PMID: 33613168 PMC: 7879264. DOI: 10.1159/000510921.

Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.

Kreisel W, Schaffner D, Lazaro A, Trebicka J, Merfort I, Schmitt-Graeff A Int J Mol Sci. 2020; 21(17).

PMID: 32872119 PMC: 7503357. DOI: 10.3390/ijms21176223.

References

Tripathi D, Hayes P . Review article: a drug therapy for the prevention of variceal haemorrhage. Aliment Pharmacol Ther. 2001; 15(3):291-310. DOI: 10.1046/j.1365-2036.2001.00920.x. View

Newby D, Hayes P . Hyperdynamic circulation in liver cirrhosis: not peripheral vasodilatation but 'splanchnic steal'. QJM. 2002; 95(12):827-30. DOI: 10.1093/qjmed/95.12.827. View

Baik S, Jeong P, Ji S, Yoo B, Kim H, Lee D . Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol. 2005; 100(3):631-5. DOI: 10.1111/j.1572-0241.2005.41381.x. View

Garcia-Tsao G, Sanyal A, Grace N, Carey W . Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007; 46(3):922-38. DOI: 10.1002/hep.21907. View

Tan J, Surti B, Saab S . Pregnancy and cirrhosis. Liver Transpl. 2008; 14(8):1081-91. DOI: 10.1002/lt.21572. View

Garcia-Pagan J, Villanueva C, Albillos A, Banares R, Morillas R, Abraldes J . Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut. 2009; 58(8):1144-50. DOI: 10.1136/gut.2008.171207. View

Tripathi D, Ferguson J, Kochar N, Leithead J, Therapondos G, McAvoy N . Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology. 2009; 50(3):825-33. DOI: 10.1002/hep.23045. View

Tripathi D, Hayes P . The role of carvedilol in the management of portal hypertension. Eur J Gastroenterol Hepatol. 2010; 22(8):905-11. DOI: 10.1097/MEG.0b013e3283367a99. View

Serste T, Melot C, Francoz C, Durand F, Rautou P, Valla D . Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010; 52(3):1017-22. DOI: 10.1002/hep.23775. View

10.

De Franchis R . Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010; 53(4):762-8. DOI: 10.1016/j.jhep.2010.06.004. View

11.

Sarin S, Sharma P . Terlipressin: an asset for hepatologists!. Hepatology. 2011; 54(2):724-8. DOI: 10.1002/hep.24519. View

12.

Lebrec D, Hillon P, Munoz C, Goldfarb G, Nouel O, Benhamou J . The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology. 1982; 2(5):523-7. DOI: 10.1002/hep.1840020502. View

13.

Laudanski T, Akerlund M . Uterine effects of N-alpha-triglycyl-(8-lysine)-vasopressin and 8-lysine-vasopressin in the first trimester of pregnancy. Contraception. 1980; 22(2):199-208. DOI: 10.1016/0010-7824(80)90064-5. View